In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
UK utility extracting glucose from used TP
In the United Kingdom, water treatment company United Utilities is trialing a process at its Blackburn sewage works to extract glucose from used toilet...
Stella McCartney takes flight with plant-based feathers
In New York, sustainability-focused designer Stella McCartney used faux feathers made from plant-based materials in fashions exhibited at the recent Paris Fashion Week.
Produced...
Artificial Nature hits milestone scaling PLH
In Germany, Artificial Nature S.L. has scaled up production of its biobased and biodegradable copolyester PLH to 300 metric tons per year. The milestone...